IronBridge Capital Management’s West Pharmaceutical WST Stock Holding History

IronBridge Capital Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$21.9M	Sell	268,421 -124,608	-32%	-$10.4M	1.33%	16
2016 Q4	$33.3M	Buy	393,029 +17,320	+5%	+$1.36M	1.49%	16
2016 Q3	$28M	Sell	375,709 -27,456	-7%	-$2.18M	1.28%	23
2016 Q2	$30.6M	Sell	403,165 -61,860	-13%	-$4.5M	1.34%	19
2016 Q1	$32.2M	Buy	465,025 +11,740	+3%	+$706K	1.3%	23
2015 Q4	$27.3M	Sell	453,285 -7,445	-2%	-$448K	1.08%	28
2015 Q3	$24.9M	Sell	460,730 -130,880	-22%	-$7.63M	0.98%	33
2015 Q2	$34.4M	Sell	591,610 -33,620	-5%	-$1.88M	1.03%	30
2015 Q1	$37.6M	Sell	625,230 -33,070	-5%	-$1.76M	1.07%	27
2014 Q4	$35M	Sell	658,300 -1,210	-0.2%	-$60.5K	0.98%	28
2014 Q3	$29.5M	Sell	659,510 -7,395	-1%	-$314K	0.78%	34
2014 Q2	$28.1M	Sell	666,905 -125,405	-16%	-$5.37M	0.69%	43
2014 Q1	$34.9M	Buy	792,310 +54,169	+7%	+$2.55M	0.76%	45
2013 Q4	$36.2M	Sell	738,141 -33,071	-4%	-$1.55M	0.77%	42
2013 Q3	$31.7M	Sell	771,212 -16,700	-2%	-$637K	0.67%	46
2013 Q2	$27.7M	Buy	+787,912	New	+$25.9M	0.54%	61

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

IronBridge Capital Management's WST Position: Q1 2017 in Review

IronBridge Capital Management reduced its West Pharmaceutical (WST) stake by 32% in Q1 2017, selling an estimated $10.4M and leaving 268,421 shares worth $21.9M. The position accounts for 1.33% of the portfolio, ranked #16.

IronBridge Capital Management first reported a position in WST in Q2 2013 and has held it in 16 quarters since. The position peaked at $37.6M in Q1 2015. 294 funds tracked by Wall St. Rank hold WST as of Q1 2017.

IronBridge Capital Management held 268,421 shares of West Pharmaceutical worth $21.9M as of Q1 2017.
IronBridge Capital Management sold 124,608 West Pharmaceutical shares in Q1 2017, an estimated $10.4M.
West Pharmaceutical made up 1.33% of IronBridge Capital Management's portfolio in Q1 2017, its #16 holding.
IronBridge Capital Management first reported a position in West Pharmaceutical in Q2 2013 and has held it in 16 quarters since.
IronBridge Capital Management's West Pharmaceutical position peaked at $37.6M in Q1 2015.
294 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2017.

Based on IronBridge Capital Management's 13F filing for Q1 2017, filed 10 May 2017.